FINANCIAL TIMES LIVE | Global Conferences & Events

## May 6, 2015

| | |
|---|---|
| 9:00 am - 9:05 am | **Opening Remarks** |
| 9:05 am - 9:30 am | **Keynote Opening Address** |
| 9:30 am - 10:20 am | **At the Cusp? Healthcare and the Future** |

Healthcare reform is the US is reaching a new level of maturity, with a growing realization the despite the ebb and flow of political maneuvering and change, reversal is unlikely and reform is here to stay. At this important juncture, what can we ascertain about how reform will transform the healthcare market in the US? Will we succeed in bending the cost curve? Will the US in the longer term move towards a universal, single payer system? Will employers become disengaged from healthcare provision? And what can be said more generally about how healthcare will be transformed in the years ahead? With significant innovations and progress underway in the field of genomics, biotechnology, digital and health technologies and age-related disease research for instance, are we nearing a tipping point of a major transformation of healthcare? Which diseases and health challenges will today's Millennials face that their parents didn't? Will dealing with the label of pre-clinical disease, for instance, become the major health dilemma for the next generation? As new models and provider of care proliferate, will the patient-doctor relationship become medicine's fastest fading commodity?

| | |
|---|---|
| 10:20 am - 11:00 am | **Pricing and Reimbursement: Surviving and Thriving in a Value Based World** |

With the recent launch of Gilead's Solvadi, a new hepatitis C drug at a costs of $ 84,000 for a 12 week course, a political debate In the US over drug pricing was unleashed, marked by what amounts to a national rebellion against the company and its drug. With the use of such high price speciality drugs expressed to rise, and pressure to curtail costs increasing, is the Solvadi case a harbinger of greater scrutiny of drug pricing in the US from payers, politicians and the public? How much it too much? Will companies have to accept lower prices than expected for specialty medicines? Will we see drug rationing with a body such as NICE in the UK, or something comparable, emerging as a gatekeeper for new medicines? Are market forces/prices the only effective way to drive medical innovation? What role could risk sharing and other value based pricing models play?

| | |
|---|---|
| 11:00 am - 11:20 am | **Networking Break** |

11:20 am - 12:10 pm **Growth and Transformation Strategies at the Intersection of Change: M&A and Beyond**

Anyone witnessing the feverish deal-making that has swept through the global life sciences and healthcare industry recently might conclude that M&A activity has become the dominant force shaping the industry. M&A, however, is just one way forward, as companies respond to change in this dynamic and innovative space. Companies are embracing a variety of approaches including investments in emerging markets, collaborations and partnerships, including with new players outside the healthcare sector in their quest for growth. What forces have been driving M&A and are they hear to stay? Has recent M&A been opportunistic or 'retooling for next decade'? Which types of deals will yield the greatest value? To what extent might regulatory and political scrutiny limit the efficiencies that can be achieved in M&A deals? Will we see more deals between big pharma rivals-what are the risk of such deals, and are they set to become commonplace? What are the patient engagement strategies healthcare companies are undertaking to ensure patient are 'front and center' to their business? Where are companies looking for tomorrow's progressive growth and what do the 'bets' new entrants are placing in the industry tell us about where future growth may come from?

12:10 pm - 1:00 pm **Biotechnology and Biosimilars**

What's next for biotech?Biotechnology is enjoying the biggest boom since the last bubble some 15 years ago. Biotech companies have led the way in deal making and important drug launches, and their strong performance has galvanised investors. Is this current boom more sustainable? What is driving the surge in IPOs and valuations-maturing science or irrational exuberance? Is the term biotech still relevant when Gilead today is bigger than GSK and Sanofi? What, if any, is the threat to the industry from the growing DIY Bio movement-how big could it become? Meanwhile the first biosimilars have been filed for approval with the FDA. Are they finally due for lift off in the US? Are biosimilars a threat or an opportunity for pharma and biotech?

1:00 pm - 2:10 pm **Lunch**

2:10 pm - 2:35 pm **Keynote Interview**

2:35 pm - 3:25 pm **Aging, Disease and the Secrets of Longevity**

A growing number of healthcare companies and investment capital is making its way into the study of aging with the aim not only of extending lifespan-or healthspan as it is more appropriately known-but also of studying the link between the processes of aging and the many diseases which afflict old age to include Alzheimers, heart disease and chronic diseases such as diabetes. What lies ahead could be a future in which centenarians could become the norm rather than the exception-when aging could possibly be 'cured', resulting in a less crippling and costly burden on the healthcare system. Where is research heading and what have been the strategies behind the companies making a move into this growing field? What new ways might emerge of diagnosing, understanding and addressing the diseases of aging? Given the lack of significant progress in tacking degenerative diseases such as Alzheimers and Parkinsons to date, what is the case for thinking success is achievable now, and what is timeline for the availability of new anti-aging medicines? What are the practical and philosophical challenges which need to be addressed before the development of ant-aging drugs arrives in earnest? With regards to the here and now business of Alzheimers, how realistic are the government goals of a disease-modifying medicine by 2025? Will investment incentives and extended patents be made available?

3:25 pm - 3:45 pm **Networking Break**

3:45 pm - 4:45 pm **The Potential and Perils of Digital Health and Cyber Security**

The wearables craze is well established, health apps are proliferating and big data is becoming a reality. Where next in the convergence of health and digital technology? Do deals such as Novartis-Google and Abbvie-Calico signal that big pharma is waking up to the opportunities and disruptive threats of digital health? One of the unintended consequences of the digitisation of healthcare and increasingly networked connectivity, however, is the heightened risk of cyber-attack compromising the availability, integrity and confidentiality of private health information, with resultant damage to reputation and brand, and the loss of patient goodwill. The healthcare industry was subjected to the largest (43%) of cyber-attacks of any industry in 2013, a 30 % increase in the previous year .Will considerations of cyber security and privacy stop the digital revolution in its tracks? What are the capability gaps of healthcare companies, and how should this challenge be addressed?

| | |
|---|---|
| 4:45 pm - 5:10 pm | **Future Vision Conclusion Address** |
| 5:10 pm - 5:15 pm | **Closing Remarks** |